Amy Archer, DO
Family Medicine · Washington, INNPI 1497972251
Payments from drug & device makers
Across 73 payments — averaging $16.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$292
- Amgen$269
- Novo Nordisk$149
- Lilly USA, LLC$62
- GSK$55
- Pfizer$46
- plus $300 from 15 others
What the payments were for
- Food & beverage$1,174100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 17 | $292 |
| Amgen | 16 | $269 |
| Novo Nordisk | 10 | $149 |
| Lilly USA, LLC | 4 | $62 |
| GSK | 4 | $55 |
| Pfizer | 4 | $46 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $39 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
| Ironshore Pharmaceuticals Inc. | 2 | $33 |
| Sunovion Pharmaceuticals Inc. | 1 | $22 |
| Bard Peripheral Vascular, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Nevro Corp. | 1 | $17 |
| Merck | 1 | $16 |
| Abbott | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Alkermes, Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
How this compares
$1,174 in reported general payments places this provider in the 60th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 45 | $61,365 |
| MounjaroTirzepatide | 50 | $49,987 |
| EliquisApixaban | 76 | $47,784 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $39,794 |
| TrulicityDulaglutide | 37 | $36,490 |
| LinzessLinaclotide | 51 | $29,384 |
| MyrbetriqMirabegron | 42 | $18,828 |
| Tresiba Flextouch U-100Insulin Degludec | 32 | $15,482 |
| JardianceEmpagliflozin | 23 | $14,981 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $13,490 |
| Advair HfaFluticasone Propion/Salmeterol | 29 | $12,111 |
| JanuviaSitagliptin Phosphate | 11 | $11,645 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 48 | $6,945 |
| BelsomraSuvorexant | 14 | $6,091 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,265 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $62 | $86,47787 claims |
| Novo NordiskOzempic | $149 | $61,36545 claims |
| PfizerEliquis | $46 | $47,78476 claims |
| GSKTrelegy Ellipta | $55 | $39,79443 claims |
| MerckJanumet, Januvia, Belsomra | $16 | $31,22637 claims |
| AbbVieLinzess | $292 | $29,38451 claims |
| Boehringer IngelheimJardiance | $14 | $14,98123 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $18 | $4,26512 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $1,788263 claims |
| Sanofi-aventis U.S. LLCLantus | $13 | $1,74930 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Washington
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
- Jonathan ConditMuncie$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.